New Teva CEO Kare Schultz is getting down to business—and quickly.
Two of Roche's newest drugs—including the just-approved hemophilia therapy Hemlibra—racked up data that bolster their case for $1 billion-plus sales.
Three major regulatory bodies – FDA, EMA and Health Canada – changed their guidelines to drug naming. How could these changes impact drug launch timelines?
Facing a rash of lawsuits claiming aggressive opioid marketing led to a nationwide epidemic, Purdue Pharma is reportedly initiating settlement talks.
Bayer's consumer health ambitions have been frustrated by declining U.S. sales, and now it's shaking up management to get the unit back on track.
Cardinal Health has agreed to sell its China business to Shanghai Pharma for $557 million in cash.
If recent numbers—and a new doctor survey—are any indication, Tesaro's Zejula has the lead in ovarian cancer. But that could change.
The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.
Pfizer bowed out of a troubled joint venture with China's Hisun Pharma, which sells branded generic drugs in China.
Pfizer now has a chief operating officer and, potentially, a successor to CEO Ian Read: Albert Bourla, who now heads its Innovative Health unit.
With cash flow under pressure, AstraZeneca could struggle to live up to CEO Pascal Soriot's commitment to pay a generous dividend "today, tomorrow,…